Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Gains from Investment Securities: 2011-2025

Historic Gains from Investment Securities for Heron Therapeutics (HRTX) over the last 9 years, with Sep 2025 value amounting to $28.9 million.

  • Heron Therapeutics' Gains from Investment Securities rose 10.45% to $28.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.9 million, marking a year-over-year increase of 10.45%. This contributed to the annual value of $8.2 million for FY2024, which is 49.67% down from last year.
  • Heron Therapeutics' Gains from Investment Securities amounted to $28.9 million in Q3 2025, which was up 22,493.80% from -$129,000 recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' Gains from Investment Securities registered a high of $29.4 million during Q1 2024, and its lowest value of -$129,000 during Q2 2025.
  • Over the past 3 years, Heron Therapeutics' median Gains from Investment Securities value was $23.8 million (recorded in 2023), while the average stood at $17.0 million.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first crashed by 100.51% in 2022, then surged by 62,653.85% in 2024.
  • Heron Therapeutics' Gains from Investment Securities (Quarterly) stood at $2.1 million in 2021, then crashed by 99.88% to $22,000 in 2022, then surged by 22,366.67% to $13,000 in 2023, then spiked by 62,653.85% to $8.2 million in 2024, then rose by 10.45% to $28.9 million in 2025.
  • Its Gains from Investment Securities stands at $28.9 million for Q3 2025, versus -$129,000 for Q2 2025 and $34,000 for Q1 2025.